ClinConnect ClinConnect Logo
Search / Trial NCT05548426

Linezolid for Syphilis Pilot Study

Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Sep 16, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Linezolid Treponema Pallidum Penicillin Early Syphilis

ClinConnect Summary

The Linezolid for Syphilis Pilot Study is a research trial aimed at exploring whether the antibiotic linezolid can effectively treat syphilis, a sexually transmitted infection. The study is currently recruiting participants who are 16 years of age or older and have been diagnosed with primary, secondary, or early latent syphilis. To be eligible, participants must also have a specific blood test result indicating the presence of the infection and, if they are living with HIV, must be on treatment with a controlled viral load.

Participants in this trial can expect to receive linezolid as part of their treatment. They will be closely monitored throughout the study, and their health will be evaluated to determine how well the medication works against syphilis. However, certain individuals cannot participate, including those who are pregnant, have specific mental health medication prescriptions, or have recent treatment with certain antibiotics. This study is an important step in finding new treatment options for syphilis and could contribute to better care for those affected by this infection.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 16 years of age or older
  • Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
  • Able to provide informed consent
  • For PLHIV: on treatment for HIV-infection and most recent viral load \<200 copies/mL or most recent CD4 T-cell count \>350 cells/mL
  • Exclusion Criteria:
  • Pregnancy or a positive pregnancy test on the day of enrollment
  • Participants who receive certain psychotropic medications, e.g., MAO inhibitors, SNRIs, SSRIs
  • Patients showing signs and symptoms of neurosyphilis
  • Serofast RPR titer
  • Recent (\<7 days) or concomitant antimicrobial therapy with azithromycin, doxycycline, ceftriaxone, cefixime, or other beta lactam antibiotics (e.g. amoxicillin)
  • Linezolid or penicillin allergy

About University Of Southern California

The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.

Locations

Jackson, Mississippi, United States

Chicago, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Jeffrey D Klausner, MD MPH

Principal Investigator

University of Southern California

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials